Objective  To investigate the anti-angiogenesis and tumor inhibitory effects of recombinant human endostatin (rhES) combined with paclitaxel-cisplatin chemotherapy (TP regimen) on xenograft tumors in nude mice of human breast carcinoma cell MCF-7.   Methods  Forty-eight xenograft nude mice were randomized into group A and group B，then every group were divided 4 subgroups

that is

TP group (cisplatin 20 mg/kg at days 1

7 and 14

and paclitaxel 5

mg/kg at days 1 and 7

i.p.)

rhES group (rhES 10 mg·kg

-1

·d

-1

for 14 d

i.v.)

rhES+TP group (combined treatment as abovementioned)

and control group (normal saline

i.v.). Inhibitory rate of xenograft and tumor growth curve was calculated and plotted. Serum VEGF level was determined by ELISA

microvessel density (MVD) in tumors was measured by immunohistochemistry

and cell apoptosis was examined by TUNEL staining. Survival time was observed in group B.   Results  Serum VEGF and MVD was significantly lower in rhES+TP group than in other groups (P0.05)

but its apoptosis index was higher (P0.05). Survival time had no difference in rhES+TP group than in TP group

but was longer than that of control group (P0.05).   Conclusion  rhES combined TP regimen is better than TP regimen in tumor growth and microvessel growth of human breast cancer xenograft

but the survival is not significant prolonged within one treatment cycle.